Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty for Hip Fracture
Latest Information Update: 04 Oct 2023
At a glance
- Drugs Emiplacel (Primary)
- Indications Muscle injury
- Focus Registrational; Therapeutic Use
- Sponsors Pluri
- 26 Sep 2023 Status changed from active, no longer recruiting to completed.
- 21 Sep 2023 Planned End Date changed from 1 Jul 2023 to 1 Sep 2023.
- 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.